Cheryl Guttman Krader, BS, Pharm

“Real talk” on new devices gives surgeons, patients decision-making insights

Monofocal toric lens delivers effective astigmatic correction and more, study results show

Study results give ophthalmologists a plan for treating patients with good vision.

Uveitic glaucoma presents a treatment challenge because of the need to control two conditions. Furthermore, side effects of conventional treatments for uveitis-corticosteroids and systemic immunomodulatory agents-limit their use.

Glaucoma genetics research can define the molecular basis of glaucoma and targets for developing curative or even preventive therapies, and it also pro-vides a basis for diagnostic and screening tests.

Innovations in procedure may overcome current technical difficulty

Treatment slows or halts the progression of keratoconus, corneal ectasia

Adding procedure can improve visual function, offer patients normal lifestyle

Research to understand underlying mechanisms may lead to clues for targeted therapy

A micro-interventional device that uses a nitinol filament can dissect any grade cataract without causing capsular stress.

Customized corneal crosslinking for keratoconus focuses the treatment on the weak area of the cornea.

The WhiteStar Signature Pro (J&J Vision) offers a diverse range of novel technologies that blend together to make cataract surgery easier, safer, and more efficient, according to Steven H. Dewey, MD.

Achieving satisfaction for patients interested in a multifocal IOL begins with comprehensive preoperative screening and evaluation.

A novel toric IOL features an aberration-free, transitional conic anterior optic surface shows pupil independence and improved tolerance to misalignment in bench testing and excellent clinical outcomes.

Trifocal IOLs can provide good uncorrected vision at near, intermediate, and far. Outcomes in a series of 30 patients show that a toric version of a trifocal IOL (AT Lisa tri 939MP, Carl Zeiss Meditec) delivers those benefits for patients with > 1 D of corneal astigmatism.

Accommodating-disaccommodating IOLs are being developed that mimic the movement of the young crystalline lens through the use of “Zonular Capture Haptics” technology.

A new non-apodized diffractive trifocal IOL allows 88% energy utilization and sends energy to near (40 cm), a preferred intermediate distance (60 cm), and far (infinity). Early results for visual acuity, contrast sensitivity, and photopic symptoms are encouraging.

Multifocal IOLs with a trifocal diffractive optic design are available outside of the United States. They provide good visual acuity for distance, intermediate, and near and appear to provide slightly better intermediate vision than bifocal diffractive multifocal IOLs.

Findings from an international trial with follow-up in some subjects now extending beyond 6 years show that a retinal prosthesis (Argus II Retinal Prosthesis System, Second Sight Medical Products) remains safe, said Allen C. Ho, MD.